SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today the completion of patient enrollment in its Phase 2a clinical trial for MB07803, a product candidate being studied as a treatment for patients with type 2 diabetes. With this trial fully enrolled and the final patients undergoing dosing, the Company expects to be able to announce top line results in the second quarter of 2008, as planned. MB07803 is a member of a new class of drugs discovered by Metabasis that is designed to regulate glucose production in the liver by inhibiting an enzyme known as fructose-1,6-bisphosphatase (FBPase), a key enzyme in the gluconeogenesis pathway which is responsible for the excessive production of glucose in patients with type 2 diabetes.
